Benzinga | Feb 4, 2021 07:04AM EST

Morgan Stanley Downgrades GW Pharmaceuticals to Equal-Weight, Raises Price Target to $220

Morgan Stanley analyst David Lebowitz downgrades GW Pharmaceuticals (NASDAQ:GWPH) from Overweight to Equal-Weight and raises the price target from $193 to $220.